PURE Bioscience Reports Increased Sales Amid Ongoing Financial Challenges in Q3 2025

Company Overview: PURE Bioscience, Inc. (OTCBB: PURE) develops and markets proprietary antimicrobial products that address health and environmental challenges.

Recent Performance Highlights:

• Q3 2025 Results:
  • Net product sales increased to $489,000 from $440,000 year-over-year.
  • Gross profit rose to $283,000, as gross margin improved despite increased sales of lower-margin products.
  • Net loss decreased to $580,000 from $857,000. Basic and diluted net loss per share was $(0.01).
• Nine-Month Summary (as of April 30, 2025):
  • Total revenue of $1,438,000, slightly down from $1,489,000 year-over-year.
  • Net loss of $2,067,000 for the period.
  • Cash and equivalents totaled $540,000, increased from $424,000 as of July 31, 2024.

Income Statement Analysis:

• Positive Aspects:
  • Reduced selling, general, and administrative expenses from $998,000 to $776,000.
  • Other income increased significantly to $82,000 from $1,000, aided by government tax credits.
• Negative Aspects:
  • Ongoing net losses indicating a need for continued financing.
  • High operating expenses, with a continuing cash burn of $1,559,000 from operating activities.

Stockholders' Deficiency: As of April 30, 2025, the stockholders' deficiency stood at $(4,814,000), indicating significant financial challenges. This raises concerns about the company's ability to continue as a going concern, as voiced by external auditors.

Future Outlook: The company aims to secure additional funding and leverage its distribution network to improve sales and mitigate operational costs. However, uncertainties regarding market acceptance and regulatory approvals remain major risks.

In summary, while PURE Bioscience, Inc. is witnessing some positive trends in sales and expense management, it remains vulnerable to financial uncertainties and requires strategic action for longer-term sustainability.